The Importance of Diagnostic and Prognostic Biomarker Identification and Classification Towards Understanding ALS...

Area of Science:

• Neuroscience
• Genetics
• Biomarker Discovery

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a complex multisystem neurodegenerative disorder with largely unknown causes.
• Current diagnosis relies on clinical and electrophysiological criteria, involving lengthy exclusion processes and diagnostic delays of 9-15 months.
• The majority of ALS cases (80%) lack identified genetic mutations, highlighting the need for advanced diagnostic and prognostic tools.

Purpose of the Study:

• To address the urgent need for improved diagnostic speed and accuracy in ALS.
• To propose a combined panel of diagnostic and prognostic biomarkers for ALS.
• To facilitate personalized medicine by enabling targeted drug development and patient stratification.

Main Methods:

• Review of current diagnostic criteria for ALS, including the Revised El Escorial Criteria, Airlie House Criteria, and Awaji Criteria.
• Analysis of existing research on genetic mutations (e.g., C9orf72, SOD1, FUS, TARDBP/TDP43) and potential causes of sporadic ALS.
• Exploration of the role of biomarkers in disease understanding, diagnosis, prognosis, and therapeutic development.

Main Results:

• Biomarkers are essential for accurate ALS diagnosis, prognosis, and understanding disease mechanisms.
• A panel of biomarkers is likely necessary to fully capture the complexity of ALS pathology.
• Biomarkers can aid in identifying patient sub-cohorts for targeted therapies and more efficient clinical trials.

Conclusions:

• The identification of specific ALS biomarkers is critical for developing a reliable and fast diagnostic test.
• Prognostic biomarkers are needed to monitor disease progression.
• Biomarker discovery is key to advancing personalized medicine in ALS treatment and clinical trial design.